Advancing European Research Infrastcuture on Highly Pathogenic Agents

Información del proyecto

ERINHA-Advance

Identificador del acuerdo de subvención: 824061

DOI

10.3030/824061

Proyecto cerrado

Fecha de la firma de la CE 20 Noviembre 2018

Fecha de inicio 1 Enero 2019

Fecha de finalización 30 Junio 2022

Financiado con arreglo a

• EXCELLENT SCIENCE - Research Infrastructures

Coste total

€ 3 746 804,14

Aportación de la UE

€ 3 746 804,14

Coordinado por

EUROPEAN RESEARCH INFRASTRUCTURE ON HIGHLY PATHOGENIC AGENTS
Belgium

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

Documents, reports (8)

Report on the activities and interest expressed from the CEE

It will also include information on actions put in place to attract CEE countries

Report on workshop with African partners

INSA Report with the description discussions and conclusions of the workshop with African partners

Report on International strategy and cooperation

It includes ERINHAs international strategy clarifying targets conditions and legal framework of international cooperation as well as information on interactions with countries and initiatives outside of Europe

ERINHA-Advance communication tools

Pack of tools for relevant ERINHA-Advance events and meetings

Users’ handbook

The document provides in userfriendly way the information on the overall services framework including the IPR Ethics quality and data information

Ethical requirements for ERINHA guidelines

It includes global ethical framework for ERINHA and specific national regulations.

ERINHA Quality management tools

It includes quality management Quality Chart audit system tools and questionnaires

Factsheet on two showcases of European countries

It includes comprehensive information of the strategies and policies develop to enable a nonBSL4 and one to be BSL4 country to become an ERINHA member

Publicaciones

Peer reviewed articles (7)

A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model

Autores: David W. Hawman, Gustaf Ahlén, K. Sofia Appelberg, Kimberly Meade-White, Patrick W. Hanley, Dana Scott, Vanessa Monteil, Stephanie Devignot, Atsushi Okumura, Friedemann Weber, Heinz Feldmann, Matti Sällberg and Ali Mirazimi
Publicado en: Nature Microbiology, 2021, ISSN 2058-5276
Editor: Nature
DOI: 10.1038/s41564-020-00815-6

Biobanks for life sciences and personalized medicine: importance of standardization, biosafety, biosecurity, and data management

Autores: Heimo Müller, Georges Dagher, Martina Loibner, Cornelia Stumptner, Penelope Kungl, Kurt Zatloukal
Publicado en: Current Opinion in Biotechnology, Edición 65, 2020, Página(s) 45-51, ISSN 0958-1669
Editor: Elsevier BV
DOI: 10.1016/j.copbio.2019.12.004

A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection

Autores: Tingting Li, Hongmin Cai, Hebang Yao, Bingjie Zhou, Ning Zhang, Martje Fentener van Vlissingen, Thijs Kuiken, Wenyu Han, Corine H. GeurtsvanKessel, Yuhuan Gong, Yapei Zhao, Quan Shen, Wenming Qin, Xiao-Xu Tian, Chao Peng, Yanling Lai, Yanxing Wang, Cedric A. J. Hutter, Shu-Ming Kuo, Juan Bao, Caixuan Liu, Yifan Wang, Audrey S. Richard, Hervé Raoul, Jiaming Lan, Markus A. Seeger, Yao Cong, Barry R
Publicado en: Nature Communications, Edición 12/1, 2021, ISSN 2041-1723
Editor: Nature Publishing Group
DOI: 10.1038/s41467-021-24905-z

Limiting factors for wearing personal protective equipment (PPE) in a health care environment evaluated in a randomised study

Autores: Martina Loibner, Sandra Hagauer, Gerold Schwantzer, Andrea Berghold, Kurt Zatloukal
Publicado en: PLOS ONE, Edición 14/1, 2019, Página(s) e0210775, ISSN 1932-6203
Editor: Public Library of Science
DOI: 10.1371/journal.pone.0210775

Uncovering a conserved vulnerability site in SARS‐CoV‐2 by a human antibody

Autores: Tingting Li, Hongmin Cai, Yapei Zhao, Yanfang Li, Yanling Lai, Hebang Yao, Liu Daisy Liu, Zhou Sun, Martje Fentener van Vlissingen, Thijs Kuiken, Corine H GeurtsvanKessel, Ning Zhang, Bingjie Zhou, Lu Lu, Yuhuan Gong, Wenming Qin, Moumita Mondal, Bowen Duan, Shiqi Xu, Audrey S Richard, Hervé Raoul, JianFeng Chen, Chenqi Xu, Ligang Wu, Haisheng Zhou, Zhong Huang, Xuechao Zhang, Jun Li, Yanyan Wang
Publicado en: EMBO Molecular Medicine, 2021, ISSN 1757-4676
Editor: John Wiley & Sons Ltd.
DOI: 10.15252/emmm.202114544

Experience Report on Different PPE Variants used in a BSL-3 Facility for Autopsies and COVID-19-Related Research

Autores: Martina Loibner
Publicado en: Journal of Infectious Diseases & Preventive Medicine, 2021, ISSN 2329-8731
Editor: Longdom Group SA

Biosafety Requirements for Autopsies of Patients with COVID-19: Example of a BSL-3 Autopsy Facility Designed for Highly Pathogenic Agents

Autores: Loibner M.,Langner C.,Regitnig P.,Gorkiewicz G., Zatloukal K.
Publicado en: Pathobiology, 2020, ISSN 1015-2008
Editor: S. Karger AG
DOI: 10.1159/000513438